{"id":"https://openalex.org/W2620176345","doi":null,"title":"Pharmacokinetics and pharmacodynamics of the prodrug stimulant lisdexamfetamine dimesylate in children and adolescents with ADHD","display_name":"Pharmacokinetics and pharmacodynamics of the prodrug stimulant lisdexamfetamine dimesylate in children and adolescents with ADHD","publication_year":2014,"publication_date":"2014-02-09","ids":{"openalex":"https://openalex.org/W2620176345","mag":"2620176345"},"language":"en","primary_location":{"id":"mag:2620176345","doi":null,"is_oa":false,"landing_page_url":"http://icnapedia.org/icnc/index.php/icnc/2014/paper/view/426","pdf_url":null,"source":{"id":"https://openalex.org/S4306497219","display_name":"13th International Child Neurology Congress (ICNC2014)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"13th International Child Neurology Congress (ICNC2014)","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078507400","display_name":"Claudia Gasparian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Claudia Gasparian","raw_affiliation_strings":["Shire, S\u00e3o Paulo, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire, S\u00e3o Paulo, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076676344","display_name":"David Coghill","orcid":"https://orcid.org/0000-0003-3017-9737","observed_orcids":["https://orcid.org/0000-0003-3017-9737"]},"institutions":[{"id":"https://openalex.org/I177639307","display_name":"University of Dundee","ror":"https://ror.org/03h2bxq36","country_code":"GB","type":"education","lineage":["https://openalex.org/I177639307"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Coghill","raw_affiliation_strings":["Division of Neuroscience, University of Dundee, UK"],"raw_orcid":"https://orcid.org/0000-0003-3017-9737","affiliations":[{"raw_affiliation_string":"Division of Neuroscience, University of Dundee, UK","institution_ids":["https://openalex.org/I177639307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078331477","display_name":"Shaw Sorooshian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155387","display_name":"Shire (Switzerland)","ror":"https://ror.org/01zz06256","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I4387155387","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Shaw Sorooshian","raw_affiliation_strings":["Shire, Eysins, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire, Eysins, Switzerland","institution_ids":["https://openalex.org/I4387155387"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113517895","display_name":"James C. Ermer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James Ermer","raw_affiliation_strings":["Shire Wayne PA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire Wayne PA USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064064053","display_name":"Ben A. Adeyi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ben Adeyi","raw_affiliation_strings":["Shire Wayne PA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire Wayne PA USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039645834","display_name":"Liza A. Squires","orcid":"https://orcid.org/0009-0004-6886-0020","observed_orcids":["https://orcid.org/0009-0004-6886-0020"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Liza Squires","raw_affiliation_strings":["Shire Wayne PA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire Wayne PA USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109098321","display_name":"Richard H. Civil","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard Civil","raw_affiliation_strings":["Shire Wayne PA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire Wayne PA USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.37531398,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lisdexamfetamine-dimesylate","display_name":"lisdexamfetamine dimesylate","score":0.996999979019165},{"id":"https://openalex.org/keywords/attention-deficit-hyperactivity-disorder","display_name":"attention deficit hyperactivity disorder","score":0.7329999804496765},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8230000138282776},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9100000262260437},{"id":"https://openalex.org/keywords/d-amphetamine","display_name":"d-amphetamine","score":0.7149999737739563},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.6000000238418579},{"id":"https://openalex.org/keywords/children-and-adolescents","display_name":"children and adolescents","score":0.6790000200271606},{"id":"https://openalex.org/keywords/oros-methylphenidate","display_name":"OROS methylphenidate","score":0.8009999990463257},{"id":"https://openalex.org/keywords/plasma-concentration","display_name":"plasma concentration","score":0.5690000057220459},{"id":"https://openalex.org/keywords/therapeutic-effects","display_name":"therapeutic effects","score":0.4269999861717224},{"id":"https://openalex.org/keywords/stimulant-medication","display_name":"stimulant medication","score":0.5},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.43799999356269836},{"id":"https://openalex.org/keywords/half-life","display_name":"half-life","score":0.4429999887943268}],"concepts":[{"id":"https://openalex.org/C2780557958","wikidata":"https://www.wikidata.org/wiki/Q211036","display_name":"Stimulant","level":2,"score":0.6810263395309448},{"id":"https://openalex.org/C2777112843","wikidata":"https://www.wikidata.org/wiki/Q422112","display_name":"Methylphenidate","level":3,"score":0.6601717472076416},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6146619319915771},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.568088710308075},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.5601823925971985},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5427153706550598},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4883560836315155},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.46677345037460327},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42245250940322876},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3390212953090668},{"id":"https://openalex.org/C2780783007","wikidata":"https://www.wikidata.org/wiki/Q181923","display_name":"Attention deficit hyperactivity disorder","level":2,"score":0.32539933919906616},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.30361807346343994},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29192501306533813},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.16549348831176758},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2620176345","doi":null,"is_oa":false,"landing_page_url":"http://icnapedia.org/icnc/index.php/icnc/2014/paper/view/426","pdf_url":null,"source":{"id":"https://openalex.org/S4306497219","display_name":"13th International Child Neurology Congress (ICNC2014)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"13th International Child Neurology Congress (ICNC2014)","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2029958335","https://openalex.org/W2304244843","https://openalex.org/W2012332062","https://openalex.org/W1996292653","https://openalex.org/W2072871224","https://openalex.org/W2560227428","https://openalex.org/W2129620184","https://openalex.org/W2184245944","https://openalex.org/W3087429211","https://openalex.org/W2118417161"],"abstract_inverted_index":{"Introduction":[0],"Data":[5],"will":[6],"be":[7],"presented":[8],"on":[9],"the":[10,18,24,96,109,139,153,164,175,182,273,277],"systemic":[11],"exposure":[12],"to":[13],"d":[15,26,46,143,280],"-amfetamine":[16,27],"and":[17,75,103,118,156,179,189,210,214,217,242],"duration":[19],"of":[20,23,53,78,207,239,260],"therapeutic":[21],"action":[22],"prodrug":[28],"lisdexamfetamine":[29],"dimesylate":[30],"(LDX).":[31],"Methods":[37],"In":[41],"study":[42],"NRP104.103,":[43,136],"plasma":[44,278],"\u2011amfetamine":[47,144,281],"was":[48,69,95],"measured":[49],"after":[50],"single":[51],"doses":[52],"LDX":[54,79,188,213,233],"(30mg,":[55,80],"50mg":[56,81],"or":[57,82],"70mg)":[58,83],"in":[59,84,135,152,163,171,263,266],"patients":[60,85,105,133,169],"(6\u201312":[61],"years)":[62,87],"with":[63,88,147,158,185,204,236,268,276],"attention-deficit/hyperactivity":[64],"disorder":[65],"(ADHD).":[66],"Study":[67],"SPD489-325":[68],"a":[70],"7-week,":[71],"randomized,":[72],"double-blind,":[73],"placebo-":[74],"active-controlled":[76],"trial":[77],"(6\u201317":[86],"ADHD.":[89],"Osmotic-release":[90],"oral":[91],"system":[92],"methylphenidate":[93],"(OROS-MPH)":[94],"reference":[97],"treatment.":[98],"On":[99],"days":[100],"0,":[101],"28":[102],"49,":[104],"were":[106,226],"assessed":[107],"using":[108],"Conners\u2019":[110],"Parent":[111],"Rating":[112],"Scale-Revised":[113],"(CPRS-R)":[114],"at":[115,122,196,244],"10:00,":[116],"14:00":[117],"18:00hrs":[119],"following":[120],"dosing":[121],"07:00hrs.":[123],"Results":[127],"Of":[131,167],"18":[132],"randomized":[134,170],"17":[137],"completed":[138,181],"study.":[140,183],"Plasma":[141],"concentrations":[145],"peaked":[146],"mean":[148,159],"T":[149],"max":[150],"range":[154,165],"3.41\u20133.58h,":[155],"declined":[157],"half-life":[160],"8.61\u20138.90h.":[166],"336":[168],"SPD489-325,":[172],"317":[173],"comprised":[174],"full":[176],"analysis":[177],"set":[178],"196":[180],"Compared":[184],"placebo,":[186],"both":[187],"OROS-MPH":[190],"treatment":[191],"significantly":[192,227],"improved":[193],"CPRS\u2011R":[194],"scores":[195,265],"all":[197],"three":[198],"assessment":[199],"times":[200],"(":[201,229],"p":[202,230],"<0.001)":[203],"effect":[205,237],"sizes":[206,238],"1.424,":[208],"1.411":[209],"1.300":[211],"for":[212,219,232],"1.036,":[215],"0.976":[216],"0.922":[218],"OROS-MPH,":[220,235],"respectively.":[221],"Post-hoc":[222],"analyses":[223],"showed":[224],"improvements":[225,262],"greater":[228],"<0.02)":[231],"than":[234],"0.387,":[240],"0.435":[241],"0.377":[243],"each":[245],"time":[246],"point.":[247],"Conclusion":[251],"Following":[255],"an":[256],"early":[257],"morning":[258],"dose":[259],"LDX,":[261],"CPRS-R":[264],"children":[267],"ADHD":[269],"are":[270],"maintained":[271],"throughout":[272],"day,":[274],"consistent":[275],"concentration-time":[282],"profile.":[283],"Supported":[286],"by":[287],"funding":[288],"from":[289],"Shire.":[290]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-06-05T00:00:00"}